Bortezomib
-
- Category :
Inorganic chemicals
- CAS NO : CAS No.: 179324-69-7
- EC NO :
- Molecular Formula : C19H25BN4O4
- Main Specifications : 99% up
- Synonyms : VELCADE;dpba;[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Bortezomib for research;N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide;N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide;Bortizomib;
Package: 25kg/drum
Uses : Bortezomib is an injection. Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo test
Molecular Structure:
Product description:
Bortezomib is an injection. Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo testing demonstrates that bortezomib delays tumor growth, including multiple myeloma. This product is used in the treatment of patients with multiple myeloma, the effectiveness is based on its efficiency.
Function:
1.Multiple myeloma
This product can be used in combination with melp halan and prednione (MP regimen) for the treatment of multiple myeloma patients who have not previously been treated and are not suitable for high-dose chemotherapy and myelosuppression; Or more than one treatment of relapsed patients with multiple myeloma.
2.Mantle cell lymphoma
This product can be used for the treatment of patients with relapsed or refractory mantle cell lymphoma. This patient received at least one treatment before using this product.
CN
Search Product